Form 10-Q · Quarterly report
Boston Scientific 10-Q, filed Aug 3, 2026
- Filed
- CIK
- 0000885725
- Accession no.
- 0000885725-26-000053
Summary
Boston Scientific reported second-quarter 2026 net sales of $5.442 billion, up 7.5% from a year earlier, and net income attributable to common stockholders of $907 million, up 13.8%. For the first six months of 2026, net sales rose 9.5% to $10.646 billion and net income attributable to common stockholders rose 52.8% to $2.247 billion, driven primarily by higher net sales and a discrete tax benefit recorded in the first quarter.
Key points
- Second-quarter reported net sales rose 7.5% to $5.442 billion, with organic growth of 7.0%.
- Second-quarter net income attributable to Boston Scientific common stockholders rose 13.8% to $907 million, and diluted EPS rose 15.2% to $0.61.
- First-half reported net sales rose 9.5% to $10.646 billion, and net income attributable to common stockholders rose 52.8% to $2.247 billion, helped by higher net sales and a discrete tax benefit recorded in the first quarter of 2026.
- Cardiovascular net sales grew 8.3% in the second quarter, led by coronary therapies including the AGENT Drug-Coated Balloon and Electrophysiology led by the Farapulse Pulsed Field Ablation System, while Urology growth was relatively flat amid volume-based procurement in China and commercial disruption in sacral neuromodulation.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2.MANAGEMENT’S DISCUSSION Executive Summary The following section describes some of our financial highlights and trends on a consolidated basis. For additional information on our business units and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. (in millions, except percentages and per share data) Three Months Ended June 30, 2026 versus 2025 2026 versus 2025 2026 2025 $ % Reported net sales $ 5,442 $ 5,061 $ 381 7.5 % Reported net income (loss) attributable to Boston Scientific common stockholders 907 797 110 13.8 % Adjusted net income (loss) attributable to Boston Scientific common stockholders (non-GAAP measure) 1,275 1,127 148 13.1 % Net…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.